Wednesday, March 23, 2022 3:08:16 PM
Why would ANVISA approving a trial is by no means an endorsement of the drug -- it means they see the drug will not be a risk for patients. That not an efficacy endorsement.
If you look at the CD12 8K it clearly shows the manipulation of the statistics when the adjusted p-values for age. That was how the subgroup analysis was claimed to be statistically significant when it wasn't.
FDA statement reprimanded the company misrepresenting and manipulating the CoV clinical trial data:
Misrepresenting -- claiming the company met trial endpoints when they didn't - CD10 NEWS endpoint
Manipulating -- using inappropriate statistical models to claim statistical significance when it wasn't (also manipulation).
Read the FDA Statement: https://www.fda.gov/drugs/drug-safety-and-availability/statement-leronlimab
You can deny the FDA Statement and Letter, but they are fully documented by the press releases and the 8K data that NP filed. FDA saw the data and told NP don't bother filing as they saw the misrepresentations and manipulations. You can deny it all you want, but FDA is the law, and LL "fought the law and the law won." FDA handed the evidence to the SEC and the DOJ and now they are investigating NP and the company.
If you look at the CD12 8K it clearly shows the manipulation of the statistics when the adjusted p-values for age. That was how the subgroup analysis was claimed to be statistically significant when it wasn't.
FDA statement reprimanded the company misrepresenting and manipulating the CoV clinical trial data:
Misrepresenting -- claiming the company met trial endpoints when they didn't - CD10 NEWS endpoint
Manipulating -- using inappropriate statistical models to claim statistical significance when it wasn't (also manipulation).
Read the FDA Statement: https://www.fda.gov/drugs/drug-safety-and-availability/statement-leronlimab
You can deny the FDA Statement and Letter, but they are fully documented by the press releases and the 8K data that NP filed. FDA saw the data and told NP don't bother filing as they saw the misrepresentations and manipulations. You can deny it all you want, but FDA is the law, and LL "fought the law and the law won." FDA handed the evidence to the SEC and the DOJ and now they are investigating NP and the company.
Recent CYDY News
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 05/21/2026 04:15:12 AM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 05/20/2026 09:08:39 PM
- CytoDyn to Present at the LD Micro Invitational XVI • GlobeNewswire Inc. • 05/15/2026 12:30:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • InvestorsHub NewsWire • 05/11/2026 01:00:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • GlobeNewswire Inc. • 05/11/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/30/2026 08:32:50 PM
- CytoDyn Announces First Patient Dosed in Expanded Access Program for Leronlimab in Triple-Negative Breast Cancer • GlobeNewswire Inc. • 04/27/2026 12:30:00 PM
- CytoDyn to Host Investor Webcast • GlobeNewswire Inc. • 04/23/2026 12:30:00 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 04/22/2026 09:21:50 PM
- CytoDyn Presents New Leronlimab Data in Metastatic Colorectal Cancer at AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/22/2026 12:30:00 PM
- CytoDyn Completes Enrollment in Phase 2 Metastatic Colorectal Cancer Study • GlobeNewswire Inc. • 04/21/2026 08:10:00 PM
- CytoDyn Presents New Leronlimab Data in Metastatic Triple-Negative Breast Cancer at AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/20/2026 12:30:00 PM
- CytoDyn to Present at the AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/14/2026 12:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 04/08/2026 09:15:18 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 04/08/2026 12:30:28 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/25/2026 09:16:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:24:23 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:23:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:22:42 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:21:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:20:57 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:20:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/24/2026 09:15:24 PM
- CytoDyn Presents at AACR Special Conference in Cancer Research: Brain Cancer • GlobeNewswire Inc. • 03/24/2026 12:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/09/2026 09:15:18 PM
